Patents Examined by Jason Nolan
  • Patent number: 8017647
    Abstract: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: September 13, 2011
    Assignees: Arrow International Limited, Zhejiang Neo-Dankong Pharmaceutical Co. Ltd.
    Inventors: Kailan Zhou, Hong Liu, Zhirong Chen, Huabin Hong, Yang Sun, Yunde Wang, Jiangchun Pan
  • Patent number: 7985762
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3—NS4A protease.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: July 26, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Patent number: 7754750
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Patent number: 7687534
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: March 30, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. Stelmach, Emma R. Parmee, James R. Tata, Keith G. Rosauer, Ronald M. Kim, Amy R. Bittner, Jiang Chang, Christopher Joseph Sinz
  • Patent number: 7683205
    Abstract: The present invention relates to an improved process for preparation of Rivastigmine of formula (I) or pharmaceutically acceptable salts thereof comprising a step of N-methylation of compound of formula (III), wherein R1=R2=H or R1=H and R2=CH3 or an acid addition salt thereof, using paraformaldehyde in the presence of Raney Nickel and hydrogen in a suitable solvent to obtain compound of formula (II).
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: March 23, 2010
    Assignee: Alembic Limited
    Inventors: Pandurang Balwant Deshpande, Kishore Khemani, Bharat Becharbhai Boda, Tushar Rajnikant Shah, Hitarth Harshendu Acharya, Parven Kumar Luthra
  • Patent number: 7671064
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: March 2, 2010
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Allison L. Zulli, Dandu R. Reddy, Diane E. Gingrich, Ming Tao, Nadine C. Becknell, James L. Diebold, Theodore L. Underiner
  • Patent number: 7667047
    Abstract: A colorant contains a crystal of a compound represented by the following formula (1): the crystal having a crystal form showing main peaks at interplanar spacings d of 3.45±0.5 ?, 3.63±0.5 ?, 4.23±0.5 ?, 6.65±0.5 ?, and 7.84±0.5 ? in powder X-ray diffraction pattern with CuK? radiation.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: February 23, 2010
    Assignee: Fuji Xerox Co., Ltd.
    Inventors: Yuka Ito, Shinji Hasegawa, Minquan Tian, Miho Watanabe, Kazuhiko Hirokawa, Kazunori Anazawa, Tomoko Miyahara, Takashi Matsubara, Makoto Furuki
  • Patent number: 7666892
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Patent number: 7655683
    Abstract: The present invention is directed to novel imidazolopyrazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: February 2, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Zhihua Sui
  • Patent number: 7652047
    Abstract: The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: January 26, 2010
    Assignee: Ardea Biosciences, Inc.
    Inventors: Hassan El Abdellaoui, Robert Tam, Huanming Chen, Varaprasad Chamakura, Dinesh Barawkar, Andreas Maderna, Zhi Hong, Stanley Lang
  • Patent number: 7652151
    Abstract: The present invention provides novel ketopyrroles having structure XXIV wherein R2 is independently at each occurrence a deuterium atom, a halogen, a nitro group, an amino group, a C3-C40 aromatic radical, a C1-C50 aliphatic radical, or a C3-C40 cyclcoaliphatic radical; “a” is an integer from 0 to 3; and X1 and X2 are independently at each occurrence a bromine atom, a hydroxy group, or the group OR10, and wherein the group R10 is independently at each occurrence a deuterium atom, a halogen, a nitro group, an amino group, a C3-C40 aromatic radical, a C1-C50 aliphatic radical, or a C3-C40 cyclcoaliphatic radical. Ketopyrroles XXIV are useful ligands for the preparation of Type (1) and Type (2) organic iridium compositions. In one aspect, the present invention provides deuterated analogs of XXIV. Organic iridium compositions are useful in the preparation optoelectronic devices, such as OLED devices and photovoltaic devices exhibiting enhanced performance characteristics.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: January 26, 2010
    Assignee: General Electric Company
    Inventor: Kelly Scott Chichak
  • Patent number: 7649008
    Abstract: Various crystal forms of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid from a solvent, and a process for production thereof are provided.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: January 19, 2010
    Assignee: Teijin Pharma Limited
    Inventors: Mitsuru Teramoto, Naoki Tsuchiya, Hiroshi Saitoh
  • Patent number: 7649094
    Abstract: The present invention provides a method of kinetic optical resolution of carboxylic acid derivatives using specific optically active catalysts. A racemic or diastereomeric mixture of carboxylic acid derivatives of the formula (A) is reacted with a nucleophile in the presence of an optically active catalyst to form an optically active nucleophile derivative of the formula (B). The catalyst is an optically active compound represented by the formula (C) or (D) [wherein R1 is a substituted or unsubstituted, saturated or unsaturated, straight-chain, branched or alicyclic aliphatic hydrocarbon group which can have a heteroatom, R2 is ethyl or vinyl, and R5 is hydrogen or methoxy respectively].
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: January 19, 2010
    Assignee: Daiso Co., Ltd.
    Inventors: Yutaka Ishii, Yasushi Miki, Yoshiro Furukawa, Satoshi Murakami
  • Patent number: 7649096
    Abstract: A process for preparing a crystalline form of linezolid is provided comprising (a) providing a solution comprising linezolid in an organic solvent having a boiling point of less than or equal to about 150° C.; (b) adding an anti-solvent having a boiling point greater than or equal to about 50° C. to the solution; and (c) recovering the crystalline form of linezolid.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: January 19, 2010
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Bobba Venkata Siva Kumar, Pravin Bhalchandra Kulkarni, Girish Bansilal Patel, Nitin Sharad Chandra Pradhan
  • Patent number: 7645884
    Abstract: Disclosed are compositions comprising at least one [benzo[4,5]imidazo(heterocycle)] compound, said [benzo[4,5]imidazo(heterocycle)] compound selected from the group consisting of structures I and II, wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, electron withdrawing group, organic group, divalent 1,2-cycloalkylidene group, or combinations thereof; “q” is independently an integer from 1-4, L is a linking group, and “r” is independently 0 or 1; said at least one [benzo[4,5]imidazo(heterocycle)] compound being present at a concentration sufficient to cause said composition to exhibit upon exposure to an excitation radiation having a wavelength of from about 330 nanometers to about 390 nanometers, a maximum fluorescence emission wavelength of greater than or equal to about 470 nanometers; and a Stokes shift of greater than or equal to about 80 nanometers; wherein the wavelengths are measured in bisphenol A polycarbonate matrix.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: January 12, 2010
    Assignee: SABIC Innovative Plastics IP B.V.
    Inventors: Yogendrasinh Chauhan, Adil Dhalla, Sriramakrishna Maruvada, Shantaram Naik, Kiran Puthamane, Meerakani Sait, Philippe Schottland, Ganapati Shankarling, Vandita Pai-paranjape
  • Patent number: 7645886
    Abstract: The invention relates in a first embodiment to a method for the manufacture of esters of the formula (I), or especially of amides of the formula (II), wherein the symbols have the meanings given in the specification, as well as other intermediates and compounds useful in the synthesis of tryptamines and other substances mentioned in the title. The synthesis methods and intermediates are useful in the synthesis of pharmaceuticals.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: Ciba Specialty Corporation
    Inventors: Ulrich Berens, Oliver Dosenbach, Daniel Sprenger
  • Patent number: 7645775
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: January 12, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert Davies, Cornelia Forster, Michael Arnost, Jian Wang
  • Patent number: 7638548
    Abstract: There are provided compounds of the general formulas wherein X, Y, R1, R2, R3 and R4 are as described herein. The compounds exhibit anticancer activity.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: December 29, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jin-Jun Liu, Zhuming Zhang
  • Patent number: 7635713
    Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Laboratoires Serono SA
    Inventors: Yihua Liao, Zhong Zhao, Gian Luca Araldi
  • Patent number: 7625944
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: December 1, 2009
    Assignee: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote